Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus dexmedetomidine for early postoperative cognitive function after coronary artery bypass grafting in elderly patients
ChiCTR2400088606Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Jining Medical University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and dexmedetomidine in post-operative cognitive decline (POCD) (3 arms), sponsored by Affiliated Hospital of Jining Medical University. Primary endpoints: MMSE score, MoCA score and 3 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR2400088606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088606.